Psilocybin News — Latest Psilocybin Therapy News & Research
In focus
Psilocybin Study Design Atlas: Choosing the Right Evidence for the Right Claim
Psilocybin News Editorial Team · October 30, 2026
Read story1 / 3
News & insights
Insight
After the Final Visit: How to Audit Claims of Lasting Psilocybin Benefit
By Psilocybin News Editorial Team · October 30, 2026
News
Cancer Distress Trials: What the Crossover Can and Cannot Establish
By Psilocybin News Editorial Team
News
Who Guessed the Assignment? Expectancy as a Measurement Problem
By Psilocybin News Editorial Team
News
When a Psilocybin Result Changes After Statistical Adjustment
By Psilocybin News Editorial Team
News
Psilocybin Study Design Atlas: Choosing the Right Evidence for the Right Claim
By Psilocybin News Editorial Team
News
A Reader’s Field Guide to Psilocybin Evidence: From Protocol to Patient Relevance
By Psilocybin News Editorial Team
News
Antidepressants and Psilocybin Trials: Why Medication Changes Need Medical Oversight
By Psilocybin News Editorial Team
Editor's picks
Selected story
Psilocybin Study Design Atlas: Choosing the Right Evidence for the Right Claim
October 30, 2026
Selected story
A Reader’s Field Guide to Psilocybin Evidence: From Protocol to Patient Relevance
October 30, 2026
Selected story
Antidepressants and Psilocybin Trials: Why Medication Changes Need Medical Oversight
October 29, 2026
Selected story
Response, Remission, Relapse: Decoding Psilocybin Depression Results
October 29, 2026
Latest headlines
The big picture
Psilocybin Versus Escitalopram: Why the Primary Endpoint and Remission Rates Tell Different Stories
October 30, 2026
Read the full storyLatest News
Psilocybin Versus Escitalopram: Why the Primary Endpoint and Remission Rates Tell Different Stories
October 30, 2026
From Trial Listing to Enrollment: The Access Bottlenecks Behind Psilocybin Research
October 30, 2026
Reading Psilocybin Adverse Events Without Confusing Frequency, Severity, and Cause
October 30, 2026
The Therapy Component in Psilocybin Trials: What Would Isolate Its Contribution?
October 30, 2026
After the Final Visit: How to Audit Claims of Lasting Psilocybin Benefit
October 30, 2026
Cancer Distress Trials: What the Crossover Can and Cannot Establish
October 30, 2026
Who Guessed the Assignment? Expectancy as a Measurement Problem
October 30, 2026
When a Psilocybin Result Changes After Statistical Adjustment
October 30, 2026
Antidepressants and Psilocybin Trials: Why Medication Changes Need Medical Oversight
October 29, 2026
Response, Remission, Relapse: Decoding Psilocybin Depression Results
October 29, 2026
Psilocybin Research Consent: Questions About Touch, Privacy and Boundaries
October 29, 2026
Can Psilocybin Depression Findings Apply to Bipolar Disorder?
October 29, 2026
Who Do Psilocybin Trial Results Represent? A Patient Guide
October 29, 2026
Psilocybin vs Escitalopram: What the Six-Month Follow-Up Adds
October 29, 2026
The Seven-Person Brain Study Behind Psilocybin Reset Headlines
October 29, 2026
Why the 2022 Psilocybin Alcohol Trial Measured Heavy-Drinking Days
October 29, 2026
Psilocybin and Smoking Cessation: Why a Small Pilot Still Needs Careful Reading
October 29, 2026
The 2006 Psilocybin OCD Study: A Signal, Not Proof of Lasting Relief
October 29, 2026
Does Psilocybin Microdosing Work? How to Read the Evidence
October 29, 2026
Psilocybin Integration: Turning an Experience Into Everyday Questions
October 29, 2026
Psilocybin, LSD, MDMA, and Ketamine: Why the Differences Matter
October 29, 2026
How to Find and Evaluate a Legitimate Psilocybin Clinical Trial
October 29, 2026